Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?

MeSH terms

• Angiotensin II Type 1 Receptor Blockers / adverse effects
• Angiotensin II Type 1 Receptor Blockers / therapeutic use*
• Angiotensin-Converting Enzyme Inhibitors / adverse effects
• Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
• Antihypertensive Agents / adverse effects
• Antihypertensive Agents / therapeutic use*
• Benzimidazoles / adverse effects
• Benzimidazoles / therapeutic use*
• Benzoates / adverse effects
• Benzoates / therapeutic use*
• Blood Pressure / drug effects*
• Clinical Trials, Phase IV as Topic
• Drug Therapy, Combination
• Humans
• Hypertension / complications
• Hypertension / drug therapy*
• Hypertension / physiopathology
• Ramipril / adverse effects
• Ramipril / therapeutic use*
• Randomized Controlled Trials as Topic
• Stroke / etiology
• Stroke / physiopathology
• Stroke / prevention & control*
• Telmisartan
• Treatment Outcome